Re: Treatment of moderate to severe hidradenitis suppurativa: In response

Annals of Internal Medicine

Volumn 159, Issue 1, 2013, Pages 72-73

  Kimball, Alexa B ^a   Gu, Yihua ^b   Okun, Martin ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b ABBVIE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

CLINICAL ASSESSMENT TOOL; CLINICAL PRACTICE; CONFLICT OF INTEREST; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; LETTER; PHYSICIAN GLOBAL ASSESSMENT; PRIORITY JOURNAL; PUBLICATION; SCORING SYSTEM; SUPPURATIVE HIDRADENITIS; TREATMENT RESPONSE; DRUG ANTAGONISM; FEMALE; MALE; NOTE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HIDRADENITIS SUPPURATIVA; HUMANS; MALE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84879569612     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-159-1-201307020-00016     Document Type: Letter

References (0)